The DOI matches its Crossref record; 784 of the 784 references it cites were found in a registry or an index.
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives
Open accessAbstract
Glioblastoma (GBM), the predominant and primary malignant intracranial tumor, poses a formidable challenge due to its immunosuppressive microenvironment, thereby confounding conventional therapeutic interventions. Despite the established treatment regimen comprising surgical intervention, radiotherapy, temozolomide administration, and the exploration of emerging modalities such as immunotherapy and integration of medicine and engineering technology therapy, the efficacy of these approaches remains constrained, resulting in suboptimal prognostic outcomes. In recent years, intensive scrutiny of the inhibitory and immunosuppressive milieu within GBM has underscored the significance of cellular constituents of the GBM microenvironment and their interactions with malignant cells and neurons. Novel immune and targeted therapy strategies have emerged, offering promising avenues for advancing GBM treatment. One pivotal mechanism orchestrating immunosuppression in GBM involves the aggregation of myeloid-derived suppressor cells (MDSCs), glioma-associated macrophage/microglia (GAM), and regulatory T cells (Tregs). Among these, MDSCs, though constituting a minority (4–8%) of CD45+ cells in GBM, play a central component in fostering immune evasion and propelling tumor progression, angiogenesis, invasion, and metastasis. MDSCs deploy intricate immunosuppressive mechanisms that adapt to the dynamic tumor microenvironment (TME). Understanding the interplay between GBM and MDSCs provides a compelling basis for therapeutic interventions. This review seeks to elucidate the immune regulatory mechanisms inherent in the GBM microenvironment, explore existing therapeutic targets, and consolidate recent insights into MDSC induction and their contribution to GBM immunosuppression. Additionally, the review comprehensively surveys ongoing clinical trials and potential treatment strategies, envisioning a future where targeting MDSCs could reshape the immune landscape of GBM. Through the synergistic integration of immunotherapy with other therapeutic modalities, this approach can establish a multidisciplinary, multi-target paradigm, ultimately improving the prognosis and quality of life in patients with GBM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–400 of 784
Targeting cellular pathways in glioblastoma multiforme
Pearson, J. R. D., & Regad, T. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.40 · Cited by 344
A Paradoxical Role for Myeloid-Derived Suppressor Cells in Sepsis and Trauma
Cuenca, A. G., Delano, M. J., Kelly-Scumpia, K. M., Moreno, C., Scumpia, P. O., LaFace, D. M., Heyworth, P. G., Efron, P. A., & Moldawer, L. L. (2011) · Molecular Medicine · doi:10.2119/molmed.2010.00178 · Cited by 340
Neutrophils and PMN-MDSC: Their biological role and interaction with stromal cells
Zhou, J., Nefedova, Y., Lei, A., & Gabrilovich, D. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2017.12.004 · Cited by 339
Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma
Chen, P., Zhao, D., Li, J., Liang, X., Li, J., Chang, A., Henry, V. K., Lan, Z., Spring, D. J., Rao, G., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.003 · Cited by 339
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
Hung, A. L., Maxwell, R., Theodros, D., Belcaid, Z., Mathios, D., Luksik, A. S., Kim, E., Wu, A., Xia, Y., Garzon-Muvdi, T., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1466769 · Cited by 336
Hitosugi, T., Fan, J., Chung, T.-W., Lythgoe, K., Wang, X., Xie, J., Ge, Q., Gu, T.-L., Polakiewicz, R. D., Roesel, J. L., et al. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.10.015 · Cited by 334
Flores-Toro, J. A., Luo, D., Gopinath, A., Sarkisian, M. R., Campbell, J. J., Charo, I. F., Singh, R., Schall, T. J., Datta, M., Jain, R. K., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910856117 · Cited by 334
Epigenetic therapy inhibits metastases by disrupting premetastatic niches
Lu, Z., Zou, J., Li, S., Topper, M. J., Tao, Y., Zhang, H., Jiao, X., Xie, W., Kong, X., Vaz, M., et al. (2020) · Nature · doi:10.1038/s41586-020-2054-x · Cited by 330
Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas
Friedman, G. K., Johnston, J. M., Bag, A. K., Bernstock, J. D., Li, R., Aban, I., Kachurak, K., Nan, L., Kang, K.-D., Totsch, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024947 · Cited by 328
Kunwar, S., Prados, M. D., Chang, S. M., Berger, M. S., Lang, F. F., Piepmeier, J. M., Sampson, J. H., Ram, Z., Gutin, P. H., Gibbons, R. D., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1117 · Cited by 325
An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers
Villa, G. R., Hulce, J. J., Zanca, C., Bi, J., Ikegami, S., Cahill, G. L., Gu, Y., Lum, K. M., Masui, K., Yang, H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.09.008 · Cited by 325
Self-citationMyeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis
Waight, J. D., Netherby, C., Hensen, M. L., Miller, A., Hu, Q., Liu, S., Bogner, P. N., Farren, M. R., Lee, K. P., Liu, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68189 · Cited by 323
IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity
Oft, M. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0214 · Cited by 322
T-cell Dysfunction in Glioblastoma: Applying a New Framework
Woroniecka, K. I., Rhodin, K. E., Chongsathidkiet, P., Keith, K. A., & Fecci, P. E. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0047 · Cited by 315
CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
Bagley, S. J., Desai, A. S., Linette, G. P., June, C. H., & O’Rourke, D. M. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy032 · Cited by 312
IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy
Weber, R., Groth, C., Lasser, S., Arkhypov, I., Petrova, V., Altevogt, P., Utikal, J., & Umansky, V. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2020.104254 · Cited by 309
Richards, L. M., Whitley, O. K. N., MacLeod, G., Cavalli, F. M. G., Coutinho, F. J., Jaramillo, J. E., Svergun, N., Riverin, M., Croucher, D. C., Kushida, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-020-00154-9 · Cited by 308
Veglia, F., Hashimoto, A., Dweep, H., Sanseviero, E., De Leo, A., Tcyganov, E., Kossenkov, A., Mulligan, C., Nam, B., Masters, G., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20201803 · Cited by 308
Therapeutic targeting of tumour myeloid cells
Barry, S. T., Gabrilovich, D. I., Sansom, O. J., Campbell, A. D., & Morton, J. P. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00546-2 · Cited by 305
Miska, J., Lee-Chang, C., Rashidi, A., Muroski, M. E., Chang, A. L., Lopez-Rosas, A., Zhang, P., Panek, W. K., Cordero, A., Han, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.029 · Cited by 304
Lu, C., Wei, Y., Wang, X., Zhang, Z., Yin, J., Li, W., Chen, L., Lyu, X., Shi, Z., Yan, W., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1137-5 · Cited by 303
Tumor infiltrating immune cells in gliomas and meningiomas
Domingues, P., González-Tablas, M., Otero, Á., Pascual, D., Miranda, D., Ruiz, L., Sousa, P., Ciudad, J., Gonçalves, J. M., Lopes, M. C., et al. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.07.019 · Cited by 302
Bleeker, F. E., Atai, N. A., Lamba, S., Jonker, A., Rijkeboer, D., Bosch, K. S., Tigchelaar, W., Troost, D., Vandertop, W. P., Bardelli, A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0645-6 · Cited by 302
Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications
Malta, T. M., de Souza, C. F., Sabedot, T. S., Silva, T. C., Mosella, M. S., Kalkanis, S. N., Snyder, J., Castro, A. V. B., & Noushmehr, H. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox183 · Cited by 302
Challenges in glioblastoma research: focus on the tumor microenvironment
Bikfalvi, A., da Costa, C. A., Avril, T., Barnier, J.-V., Bauchet, L., Brisson, L., Cartron, P. F., Castel, H., Chevet, E., Chneiweiss, H., et al. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2022.09.005 · Cited by 302
Robert, S. M., Buckingham, S. C., Campbell, S. L., Robel, S., Holt, K. T., Ogunrinu-Babarinde, T., Warren, P. P., White, D. M., Reid, M. A., Eschbacher, J. M., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa8103 · Cited by 301
Sun, C., Yin, J., Fang, Y., Chen, J., Jeong, K. J., Chen, X., Vellano, C. P., Ju, Z., Zhao, W., Zhang, D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.01.019 · Cited by 300
Self-citationRaber, P. L., Thevenot, P., Sierra, R., Wyczechowska, D., Halle, D., Ramirez, M. E., Ochoa, A. C., Fletcher, M., Velasco, C., Wilk, A., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28622 · Cited by 297
Chen, C., Jing, W., Chen, Y., Wang, G., Abdalla, M., Gao, L., Han, M., Shi, C., Li, A., Sun, P., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn1128 · Cited by 291
ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma
Koschmann, C., Calinescu, A.-A., Nunez, F. J., Mackay, A., Fazal-Salom, J., Thomas, D., Mendez, F., Kamran, N., Dzaman, M., Mulpuri, L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aac8228 · Cited by 290
Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression
Yeo, A. T., Rawal, S., Delcuze, B., Christofides, A., Atayde, A., Strauss, L., Balaj, L., Rogers, V. A., Uhlmann, E. J., Varma, H., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01215-0 · Cited by 290
Oncometabolite d -2HG alters T cell metabolism to impair CD8 + T cell function
Notarangelo, G., Spinelli, J. B., Perez, E. M., Baker, G. J., Kurmi, K., Elia, I., Stopka, S. A., Baquer, G., Lin, J.-R., Golby, A. J., et al. (2022) · Science · doi:10.1126/science.abj5104 · Cited by 289
Guo, X., Qiu, W., Liu, Q., Qian, M., Wang, S., Zhang, Z., Gao, X., Chen, Z., Xue, H., & Li, G. (2018) · Oncogene · doi:10.1038/s41388-018-0261-9 · Cited by 287
The blood–tumour barrier in cancer biology and therapy
Steeg, P. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00529-6 · Cited by 287
Greene, S., Robbins, Y., Mydlarz, W. K., Huynh, A. P., Schmitt, N. C., Friedman, J., Horn, L. A., Palena, C., Schlom, J., Maeda, D. Y., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-2625 · Cited by 280
Sattiraju, A., Kang, S., Giotti, B., Chen, Z., Marallano, V. J., Brusco, C., Ramakrishnan, A., Shen, L., Tsankov, A. M., Hambardzumyan, D., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.017 · Cited by 279
Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α
Wang, Q., He, Z., Huang, M., Liu, T., Wang, Y., Xu, H., Duan, H., Ma, P., Zhang, L., Zamvil, S. S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03050-0 · Cited by 277
Extracellular vesicle-mediated transfer of functional RNA in the tumor microenvironment
Ridder, K., Sevko, A., Heide, J., Dams, M., Rupp, A.-K., Macas, J., Starmann, J., Tjwa, M., Plate, K. H., Sültmann, H., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008371 · Cited by 276
HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC- Driven Medulloblastoma
Pei, Y., Liu, K.-W., Wang, J., Garancher, A., Tao, R., Esparza, L. A., Maier, D. L., Udaka, Y. T., Murad, N., Morrissy, S., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.011 · Cited by 276
Clinical trial links oncolytic immunoactivation to survival in glioblastoma
Ling, A. L., Solomon, I. H., Landivar, A. M., Nakashima, H., Woods, J. K., Santos, A., Masud, N., Fell, G., Mo, X., Yilmaz, A. S., et al. (2023) · Nature · doi:10.1038/s41586-023-06623-2 · Cited by 276
Liu, Y., Lai, L., Chen, Q., Song, Y., Xu, S., Ma, F., Wang, X., Wang, J., Yu, H., Cao, X., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103505 · Cited by 272
Pombo Antunes, A. R., Scheyltjens, I., Duerinck, J., Neyns, B., Movahedi, K., & Van Ginderachter, J. A. (2020) · eLife · doi:10.7554/elife.52176 · Cited by 272
Research Advances in How the cGAS-STING Pathway Controls the Cellular Inflammatory Response
Wan, D., Jiang, W., & Hao, J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00615 · Cited by 270
Grabowski, M. M., Sankey, E. W., Ryan, K. J., Chongsathidkiet, P., Lorrey, S. J., Wilkinson, D. S., & Fecci, P. E. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03483-y · Cited by 270
Johnson, A., Severson, E., Gay, L., Vergilio, J.-A., Elvin, J., Suh, J., Daniel, S., Covert, M., Frampton, G. M., Hsu, S., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0242 · Cited by 269
Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis
Cui, X., Morales, R.-T. T., Qian, W., Wang, H., Gagner, J.-P., Dolgalev, I., Placantonakis, D., Zagzag, D., Cimmino, L., Snuderl, M., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.01.053 · Cited by 267
Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment
Tian, X., Shen, H., Li, Z., Wang, T., & Wang, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0772-z · Cited by 264
Functional states of myeloid cells in cancer
van Vlerken-Ysla, L., Tyurina, Y. Y., Kagan, V. E., & Gabrilovich, D. I. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.009 · Cited by 261
Qian, J., Wang, C., Wang, B., Yang, J., Wang, Y., Luo, F., Xu, J., Zhao, C., Liu, R., & Chu, Y. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1330-2 · Cited by 260
Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion
Jiang, N., Xie, B., Xiao, W., Fan, M., Xu, S., Duan, Y., Hamsafar, Y., Evans, A. C., Huang, J., Zhou, W., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29137-3 · Cited by 258
Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma
Zhang, Q., Ma, C., Duan, Y., Heinrich, B., Rosato, U., Diggs, L. P., Ma, L., Roy, S., Fu, Q., Brown, Z. J., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0304 · Cited by 257
Frontiers in the treatment of glioblastoma: Past, present and emerging
Janjua, T. I., Rewatkar, P., Ahmed-Cox, A., Saeed, I., Mansfeld, F. M., Kulshreshtha, R., Kumeria, T., Ziegler, D. S., Kavallaris, M., Mazzieri, R., et al. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.012 · Cited by 257
Xiang, H., Ramil, C. P., Hai, J., Zhang, C., Wang, H., Watkins, A. A., Afshar, R., Georgiev, P., Sze, M. A., Song, X. S., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0507 · Cited by 256
Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas.
Debinski, W., Gibo, D. M., Hulet, S. W., Connor, J. R., & Gillespie, G. Y. (1999) · PubMed · Cited by 254
PIK3CA variants selectively initiate brain hyperactivity during gliomagenesis
Yu, K., Lin, C.-C. J., Hatcher, A., Lozzi, B., Kong, K., Huang-Hobbs, E., Cheng, Y.-T., Beechar, V. B., Zhu, W., Zhang, Y., et al. (2020) · Nature · doi:10.1038/s41586-020-1952-2 · Cited by 253
Verdugo, E., Puerto, I., & Medina, M. Á. (2022) · Cancer Communications · doi:10.1002/cac2.12361 · Cited by 253
Cancer Stemness Meets Immunity: From Mechanism to Therapy
Chen, P., Hsu, W.-H., Han, J., Xia, Y., & DePinho, R. A. (2021) · Cell Reports · doi:10.1016/j.celrep.2020.108597 · Cited by 252
NF1 mutation drives neuronal activity-dependent initiation of optic glioma
Pan, Y., Hysinger, J. D., Barron, T., Schindler, N. F., Cobb, O., Guo, X., Yalçın, B., Anastasaki, C., Mulinyawe, S. B., Ponnuswami, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03580-6 · Cited by 251
Lee, A. H., Sun, L., Mochizuki, A. Y., Reynoso, J. G., Orpilla, J., Chow, F., Kienzler, J. C., Everson, R. G., Nathanson, D. A., Bensinger, S. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26940-2 · Cited by 251
Cancer stem cells in glioblastoma—molecular signaling and therapeutic targeting
Huang, Z., Cheng, L., Guryanova, O. A., Wu, Q., & Bao, S. (2010) · Protein & Cell · doi:10.1007/s13238-010-0078-y · Cited by 248
Zhao, P., Wang, Y., Kang, X., Wu, A., Yin, W., Tang, Y., Wang, J., Zhang, M., Duan, Y., & Huang, Y. (2018) · Chemical Science · doi:10.1039/c7sc04853j · Cited by 248
T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma
Chow, K. K., Naik, S., Kakarla, S., Brawley, V. S., Shaffer, D. R., Yi, Z., Rainusso, N., Wu, M.-F., Liu, H., Kew, Y., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2012.210 · Cited by 245
Otvos, B., Silver, D. J., Mulkearns-Hubert, E. E., Alvarado, A. G., Turaga, S. M., Sorensen, M. D., Rayman, P., Flavahan, W. A., Hale, J. S., Stoltz, K., et al. (2016) · Stem Cells · doi:10.1002/stem.2393 · Cited by 245
Reilley, M. J., McCoon, P., Cook, C., Lyne, P., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0436-5 · Cited by 245
Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner
Bayik, D., Zhou, Y., Park, C., Hong, C., Vail, D., Silver, D. J., Lauko, A., Roversi, G., Watson, D. C., Lo, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1355 · Cited by 245
DHHC9-mediated GLUT1 S-palmitoylation promotes glioblastoma glycolysis and tumorigenesis
Zhang, Z., Li, X., Yang, F., Chen, C., Liu, P., Ren, Y., Sun, P., Wang, Z., You, Y., Zeng, Y.-X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26180-4 · Cited by 245
Rodrigues, J. C., Gonzalez, G. C., Zhang, L., Ibrahim, G., Kelly, J. J., Gustafson, M. P., Lin, Y., Dietz, A. B., Forsyth, P. A., Yong, V. W., et al. (2010) · Neuro-Oncology · doi:10.1093/neuonc/nop023 · Cited by 244
Chiu, D. K., Xu, I. M., Lai, R. K., Tse, A. P., Wei, L. L., Koh, H., Li, L. L., Lee, D., Lo, R. C., Wong, C., et al. (2016) · Hepatology · doi:10.1002/hep.28655 · Cited by 241
Gustafson, M. P., Lin, Y., New, K. C., Bulur, P. A., O'Neill, B. P., Gastineau, D. A., & Dietz, A. B. (2010) · Neuro-Oncology · doi:10.1093/neuonc/noq001 · Cited by 239
Schott, A. F., Goldstein, L. J., Cristofanilli, M., Ruffini, P. A., McCanna, S., Reuben, J. M., Perez, R. P., Kato, G., & Wicha, M. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2748 · Cited by 238
Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy
Sun, L., Clavijo, P. E., Robbins, Y., Patel, P., Friedman, J., Greene, S., Das, R., Silvin, C., Van Waes, C., Horn, L. A., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126853 · Cited by 237
Maurer, G. D., Brucker, D. P., Bähr, O., Harter, P. N., Hattingen, E., Walenta, S., Mueller-Klieser, W., Steinbach, J. P., & Rieger, J. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-315 · Cited by 236
Exosomes and Nanoengineering: A Match Made for Precision Therapeutics
Tran, P. H. L., Xiang, D., Tran, T. T. D., Yin, W., Zhang, Y., Kong, L., Chen, K., Sun, M., Li, Y., Hou, Y., et al. (2020) · Advanced Materials · doi:10.1002/adma.201904040 · Cited by 236
Dong, F., Qin, X., Wang, B., Li, Q., Hu, J., Cheng, X., Guo, D., Cheng, F., Fang, C., Tan, Y., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1456 · Cited by 236
Ren, Y., Huang, Z., Zhou, L., Xiao, P., Song, J., He, P., Xie, C., Zhou, R., Li, M., Dong, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36707-6 · Cited by 236
Wang, J., De Veirman, K., Faict, S., Frassanito, M. A., Ribatti, D., Vacca, A., & Menu, E. (2016) · The Journal of Pathology · doi:10.1002/path.4712 · Cited by 231
The landscape of bispecific T cell engager in cancer treatment
Zhou, S., Liu, M., Ren, F., Meng, X., & Yu, J. (2021) · Biomarker Research · doi:10.1186/s40364-021-00294-9 · Cited by 229
Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas
Friedrich, M., Sankowski, R., Bunse, L., Kilian, M., Green, E., Ramallo Guevara, C., Pusch, S., Poschet, G., Sanghvi, K., Hahn, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00201-z · Cited by 226
Targeting the Tumor Microenvironment in Cancer: Why Hyaluronidase Deserves a Second Look
Whatcott, C. J., Han, H., Posner, R. G., Hostetter, G., & Von Hoff, D. D. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0136 · Cited by 223
Harnessing the immune system in glioblastoma
Brown, N. F., Carter, T. J., Ottaviani, D., & Mulholland, P. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0258-8 · Cited by 223
Chang, Y., Cai, X., Syahirah, R., Yao, Y., Xu, Y., Jin, G., Bhute, V. J., Torregrosa-Allen, S., Elzey, B. D., Won, Y.-Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37872-4 · Cited by 222
Radiogenomics to characterize regional genetic heterogeneity in glioblastoma
Hu, L. S., Ning, S., Eschbacher, J. M., Baxter, L. C., Gaw, N., Ranjbar, S., Plasencia, J., Dueck, A. C., Peng, S., Smith, K. A., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now135 · Cited by 221
Unique pattern of neutrophil migration and function during tumor progression
Patel, S., Fu, S., Mastio, J., Dominguez, G. A., Purohit, A., Kossenkov, A., Lin, C., Alicea-Torres, K., Sehgal, M., Nefedova, Y., et al. (2018) · Nature Immunology · doi:10.1038/s41590-018-0229-5 · Cited by 220
Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials
Chu, X., Tian, W., Wang, Z., Zhang, J., & Zhou, R. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01800-3 · Cited by 220
Yu, J., Wang, Y., Yan, F., Zhang, P., Li, H., Zhao, H., Yan, C., Yan, F., & Ren, X. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400833 · Cited by 219
Christmas, B. J., Rafie, C. I., Hopkins, A. C., Scott, B. A., Ma, H. S., Cruz, K. A., Woolman, S., Armstrong, T. D., Connolly, R. M., Azad, N. A., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0070 · Cited by 219
Wang, G., Zhang, Z., Zhong, K., Wang, Z., Yang, N., Tang, X., Li, H., Lu, Q., Wu, Z., Yuan, B., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2022.08.021 · Cited by 219
Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets
Lang, S., Bruderek, K., Kaspar, C., Höing, B., Kanaan, O., Dominas, N., Hussain, T., Droege, F., Eyth, C., Hadaschik, B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3726 · Cited by 216
Circadian Regulator CLOCK Recruits Immune-Suppressive Microglia into the GBM Tumor Microenvironment
Chen, P., Hsu, W.-H., Chang, A., Tan, Z., Lan, Z., Zhou, A., Spring, D. J., Lang, F. F., Wang, Y. A., & DePinho, R. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0400 · Cited by 215
Mohamed, E., Sierra, R. A., Trillo-Tinoco, J., Cao, Y., Innamarato, P., Payne, K. K., de Mingo Pulido, A., Mandula, J., Zhang, S., Thevenot, P., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.004 · Cited by 215
Dolma, S., Selvadurai, H. J., Lan, X., Lee, L., Kushida, M., Voisin, V., Whetstone, H., So, M., Aviv, T., Park, N., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.002 · Cited by 214
TP53 gain-of-function mutation promotes inflammation in glioblastoma
Ham, S. W., Jeon, H.-Y., Jin, X., Kim, E.-J., Kim, J.-K., Shin, Y. J., Lee, Y., Kim, S. H., Lee, S. Y., Seo, S., et al. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0126-3 · Cited by 213
Davis, R. J., Moore, E. C., Clavijo, P. E., Friedman, J., Cash, H., Chen, Z., Silvin, C., Van Waes, C., & Allen, C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2534 · Cited by 213
Park, N. I., Guilhamon, P., Desai, K., McAdam, R. F., Langille, E., O’Connor, M., Lan, X., Whetstone, H., Coutinho, F. J., Vanner, R. J., et al. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.06.004 · Cited by 213
Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches
Uddin, M. S., Mamun, A. A., Alghamdi, B. S., Tewari, D., Jeandet, P., Sarwar, M. S., & Ashraf, G. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.015 · Cited by 213
An expanded universe of cancer targets
Hahn, W. C., Bader, J. S., Braun, T. P., Califano, A., Clemons, P. A., Druker, B. J., Ewald, A. J., Fu, H., Jagu, S., Kemp, C. J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.02.020 · Cited by 213
CD70, a novel target of CAR T-cell therapy for gliomas
Jin, L., Ge, H., Long, Y., Yang, C., Chang, Y. (., Mu, L., Sayour, E. J., De Leon, G., Wang, Q. J., Yang, J. C., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox116 · Cited by 211
Braun, C. J., Stanciu, M., Boutz, P. L., Patterson, J. C., Calligaris, D., Higuchi, F., Neupane, R., Fenoglio, S., Cahill, D. P., Wakimoto, H., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.08.018 · Cited by 208
Histone lactylation: epigenetic mark of glycolytic switch
Dai, X., Lv, X., Thompson, E. W., & Ostrikov, K. (. (2022) · Trends in Genetics · doi:10.1016/j.tig.2021.09.009 · Cited by 203
RORC1 Regulates Tumor-Promoting “Emergency” Granulo-Monocytopoiesis
Strauss, L., Sangaletti, S., Consonni, F. M., Szebeni, G., Morlacchi, S., Totaro, M. G., Porta, C., Anselmo, A., Tartari, S., Doni, A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.006 · Cited by 199
Liu, G., Bi, Y., Shen, B., Yang, H., Zhang, Y., Wang, X., Liu, H., Lu, Y., Liao, J., Chen, X., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2584 · Cited by 199
Self-citationHER-2, gp100, and MAGE-1 Are Expressed in Human Glioblastoma and Recognized by Cytotoxic T Cells
Liu, G., Ying, H., Zeng, G., Wheeler, C. J., Black, K. L., & Yu, J. S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3504 · Cited by 198
Sevenich, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00697 · Cited by 198
Van Den Bent, M., Eoli, M., Sepulveda, J. M., Smits, M., Walenkamp, A., Frenel, J.-S., Franceschi, E., Clement, P. M., Chinot, O., De Vos, F., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noz222 · Cited by 198
Nitric Oxide Signaling in T Cell-Mediated Immunity
García-Ortiz, A., & Serrador, J. M. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.02.002 · Cited by 197
Alban, T. J., Alvarado, A. G., Sorensen, M. D., Bayik, D., Volovetz, J., Serbinowski, E., Mulkearns-Hubert, E. E., Sinyuk, M., Hale, J. S., Onzi, G. R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122264 · Cited by 197
Ye, L., Park, J. J., Dong, M. B., Yang, Q., Chow, R. D., Peng, L., Du, Y., Guo, J., Dai, X., Wang, G., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0246-4 · Cited by 197
Remote neuronal activity drives glioma progression through SEMA4F
Huang-Hobbs, E., Cheng, Y.-T., Ko, Y., Luna-Figueroa, E., Lozzi, B., Taylor, K. R., McDonald, M., He, P., Chen, H.-C., Yang, Y., et al. (2023) · Nature · doi:10.1038/s41586-023-06267-2 · Cited by 195
Méndez, O., Zavadil, J., Esencay, M., Lukyanov, Y., Santovasi, D., Wang, S.-C., Newcomb, E. W., & Zagzag, D. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-133 · Cited by 193
Role of Notch Signaling Pathway in Glioblastoma Pathogenesis
Bazzoni, R., & Bentivegna, A. (2019) · Cancers · doi:10.3390/cancers11030292 · Cited by 193
Delgado‐Martín, B., & Medina, M. Á. (2020) · Advanced Science · doi:10.1002/advs.201902971 · Cited by 191
CDKN2A deletion remodels lipid metabolism to prime glioblastoma for ferroptosis
Minami, J. K., Morrow, D., Bayley, N. A., Fernandez, E. G., Salinas, J. J., Tse, C., Zhu, H., Su, B., Plawat, R., Jones, A., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.05.001 · Cited by 191
Cen, L., Carlson, B. L., Schroeder, M. A., Ostrem, J. L., Kitange, G. J., Mladek, A. C., Fink, S. R., Decker, P. A., Wu, W., Kim, J.-S., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos114 · Cited by 189
OuYang, L.-Y., Wu, X.-J., Ye, S.-B., Zhang, R.-X., Li, Z.-L., Liao, W., Pan, Z.-Z., Zheng, L.-M., Zhang, X.-S., Wang, Z., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0410-7 · Cited by 189
Ravi, A., Hellmann, M. D., Arniella, M. B., Holton, M., Freeman, S. S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01355-5 · Cited by 188
Hossain, D. M. S., Pal, S. K., Moreira, D., Duttagupta, P., Zhang, Q., Won, H., Jones, J., D'Apuzzo, M., Forman, S., & Kortylewski, M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3145 · Cited by 187
Palazón, A., Martínez-Forero, I., Teijeira, A., Morales-Kastresana, A., Alfaro, C., Sanmamed, M. F., Perez-Gracia, J. L., Peñuelas, I., Hervás-Stubbs, S., Rouzaut, A., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0314 · Cited by 187
Recent progress in TGF-β inhibitors for cancer therapy
Huang, C.-Y., Chung, C.-L., Hu, T.-H., Chen, J.-J., Liu, P.-F., & Chen, C.-L. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111046 · Cited by 187
The Interplay between Glioblastoma and Its Microenvironment
Dapash, M., Hou, D., Castro, B. A., Lee-Chang, C., & Lesniak, M. S. (2021) · Cells · doi:10.3390/cells10092257 · Cited by 187
Marcus, H. J., Carpenter, K. L. H., Price, S. J., & Hutchinson, P. J. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9990-5 · Cited by 186
Pellegatta, S., Savoldo, B., Di Ianni, N., Corbetta, C., Chen, Y., Patané, M., Sun, C., Pollo, B., Ferrone, S., DiMeco, F., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao2731 · Cited by 186
GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment
Halaby, M. J., Hezaveh, K., Lamorte, S., Ciudad, M. T., Kloetgen, A., MacLeod, B. L., Guo, M., Chakravarthy, A., Medina, T. D. S., Ugel, S., et al. (2019) · Science Immunology · doi:10.1126/sciimmunol.aax8189 · Cited by 186
Zika Virus Targets Glioblastoma Stem Cells through a SOX2-Integrin αvβ5 Axis
Zhu, Z., Mesci, P., Bernatchez, J. A., Gimple, R. C., Wang, X., Schafer, S. T., Wettersten, H. I., Beck, S., Clark, A. E., Wu, Q., et al. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2019.11.016 · Cited by 186
Joshi, B. H., Plautz, G. E., & Puri, R. K. (2000) · PubMed · Cited by 185
Advances in antibody-based therapy in oncology
Zinn, S., Vazquez-Lombardi, R., Zimmermann, C., Sapra, P., Jermutus, L., & Christ, D. (2023) · Nature Cancer · doi:10.1038/s43018-023-00516-z · Cited by 184
Review: ICSBP/IRF-8: Its Regulatory Roles in the Development of Myeloid Cells
Tamura, T., & Ozato, K. (2002) · Journal of Interferon & Cytokine Research · doi:10.1089/107999002753452755 · Cited by 183
Fenstermaker, R. A., Ciesielski, M. J., Qiu, J., Yang, N., Frank, C. L., Lee, K. P., Mechtler, L. R., Belal, A., Ahluwalia, M. S., & Hutson, A. D. (2016) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-016-1890-x · Cited by 183
Wang, D., Prager, B. C., Gimple, R. C., Aguilar, B., Alizadeh, D., Tang, H., Lv, D., Starr, R., Brito, A., Wu, Q., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1243 · Cited by 183
Hormigo, A., Gu, B., Karimi, S., Riedel, E., Panageas, K. S., Edgar, M. A., Tanwar, M. K., Rao, J. S., Fleisher, M., DeAngelis, L. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0181 · Cited by 182
CCR5+ Myeloid-Derived Suppressor Cells Are Enriched and Activated in Melanoma Lesions
Blattner, C., Fleming, V., Weber, R., Himmelhan, B., Altevogt, P., Gebhardt, C., Schulze, T. J., Razon, H., Hawila, E., Wildbaum, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0348 · Cited by 182
Budhwani, M., Mazzieri, R., & Dolcetti, R. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00322 · Cited by 181
Rahaman, S. O., Sharma, P., Harbor, P. C., Aman, M. J., Vogelbaum, M. A., & Haque, S. J. (2002) · PubMed · Cited by 180
Targeting MIF in Cancer: Therapeutic Strategies, Current Developments, and Future Opportunities
O'Reilly, C., Doroudian, M., Mawhinney, L., & Donnelly, S. C. (2016) · Medicinal Research Reviews · doi:10.1002/med.21385 · Cited by 180
A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma
Fan, Q., Aksoy, O., Wong, R. A., Ilkhanizadeh, S., Novotny, C. J., Gustafson, W. C., Truong, A. Y.-Q., Cayanan, G., Simonds, E. F., Haas-Kogan, D., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.01.014 · Cited by 180
De Boeck, A., Ahn, B. Y., D’Mello, C., Lun, X., Menon, S. V., Alshehri, M. M., Szulzewsky, F., Shen, Y., Khan, L., Dang, N. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18569-4 · Cited by 180
Lu-Emerson, C., Duda, D. G., Emblem, K. E., Taylor, J. W., Gerstner, E. R., Loeffler, J. S., Batchelor, T. T., & Jain, R. K. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.9575 · Cited by 179
Surace, L., Lysenko, V., Fontana, A. O., Cecconi, V., Janssen, H., Bicvic, A., Okoniewski, M., Pruschy, M., Dummer, R., Neefjes, J., et al. (2015) · Immunity · doi:10.1016/j.immuni.2015.03.009 · Cited by 179
MicroRNA-155 and MicroRNA-21 Promote the Expansion of Functional Myeloid-Derived Suppressor Cells
Li, L., Zhang, J., Diao, W., Wang, D., Wei, Y., Zhang, C.-Y., & Zen, K. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301309 · Cited by 179
Voloshin, T., Kaynan, N., Davidi, S., Porat, Y., Shteingauz, A., Schneiderman, R. S., Zeevi, E., Munster, M., Blat, R., Tempel Brami, C., et al. (2020) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02534-7 · Cited by 179
Kwak, T., Wang, F., Deng, H., Condamine, T., Kumar, V., Perego, M., Kossenkov, A., Montaner, L. J., Xu, X., Xu, W., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108571 · Cited by 178
Lucio-Eterovic, A. K., Cortez, M. A. A., Valera, E. T., Motta, F., Queiróz, R. G. D. P., Machado, H. R., Carlotti, C. G., Neder, L., Scrideli, C. A., & Tone, L. G. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-243 · Cited by 177
de Souza, C. F., Sabedot, T. S., Malta, T. M., Stetson, L., Morozova, O., Sokolov, A., Laird, P. W., Wiznerowicz, M., Iavarone, A., Snyder, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.107 · Cited by 177
Ward, Y., Lake, R. G., Yin, J. J., Heger, C. D., Raffeld, M. A., Goldsmith, P. K., Merino, M. J., & Kelly, K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-2381 · Cited by 176
Kaffes, I., Szulzewsky, F., Chen, Z., Herting, C. J., Gabanic, B., Vega, J. E. V., Shelton, J., Switchenko, J. M., Ross, J., McSwain, L., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1655360 · Cited by 176
Microglia promote glioblastoma via mTOR‐mediated immunosuppression of the tumour microenvironment
Dumas, A. A., Pomella, N., Rosser, G., Guglielmi, L., Vinel, C., Millner, T. O., Rees, J. H., Aley, N., Sheer, D., Wei, J., et al. (2020) · The EMBO Journal · doi:10.15252/embj.2019103790 · Cited by 176
Pencheva, N., Buss, C. G., Posada, J., Merghoub, T., & Tavazoie, S. F. (2014) · Cell · doi:10.1016/j.cell.2014.01.038 · Cited by 175
Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic
Grover, A., Sanseviero, E., Timosenko, E., & Gabrilovich, D. I. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0764 · Cited by 175
Crane, C. A., Austgen, K., Haberthur, K., Hofmann, C., Moyes, K. W., Avanesyan, L., Fong, L., Campbell, M. J., Cooper, S., Oakes, S. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1413933111 · Cited by 174
Miao, H., Gale, N. W., Guo, H., Qian, J., Petty, A., Kaspar, J., Murphy, A. J., Valenzuela, D. M., Yancopoulos, G., Hambardzumyan, D., et al. (2015) · Oncogene · doi:10.1038/onc.2013.590 · Cited by 174
Escape Artists of the X Chromosome
Balaton, B. P., & Brown, C. J. (2016) · Trends in Genetics · doi:10.1016/j.tig.2016.03.007 · Cited by 173
Transmembrane TNF-α Promotes Suppressive Activities of Myeloid-Derived Suppressor Cells via TNFR2
Hu, X., Li, B., Li, X., Zhao, X., Wan, L., Lin, G., Yu, M., Wang, J., Jiang, X., Feng, W., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1203195 · Cited by 172
Glutamate and α-ketoglutarate: key players in glioma metabolism
Maus, A., & Peters, G. J. (2016) · Amino Acids · doi:10.1007/s00726-016-2342-9 · Cited by 172
A circadian clock regulates efflux by the blood-brain barrier in mice and human cells
Zhang, S., Lahens, N. F., Yue, Z., Arnold, D. M., Pakstis, P. P., Schwarz, J. E., & Sehgal, A. (2021) · Nature Communications · doi:10.1038/s41467-020-20795-9 · Cited by 172
Perrin, S. L., Samuel, M. S., Koszyca, B., Brown, M. P., Ebert, L. M., Oksdath, M., & Gomez, G. A. (2019) · Biochemical Society Transactions · doi:10.1042/bst20180444 · Cited by 171
Lee-Chang, C., Rashidi, A., Miska, J., Zhang, P., Pituch, K. C., Hou, D., Xiao, T., Fischietti, M., Kang, S. J., Appin, C. L., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0240 · Cited by 171
Yu, S. J., Ma, C., Heinrich, B., Brown, Z. J., Sandhu, M., Zhang, Q., Fu, Q., Agdashian, D., Rosato, U., Korangy, F., et al. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.040 · Cited by 170
Janku, F., Zhang, H. H., Pezeshki, A., Goel, S., Murthy, R., Wang-Gillam, A., Shepard, D. R., Helgason, T., Masters, T., Hong, D. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2065 · Cited by 170
IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity
Alizadeh, D., Wong, R. A., Gholamin, S., Maker, M., Aftabizadeh, M., Yang, X., Pecoraro, J. R., Jeppson, J. D., Wang, D., Aguilar, B., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1661 · Cited by 170
Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling
Zhang, X.-N., Yang, K.-D., Chen, C., He, Z.-C., Wang, Q.-H., Feng, H., Lv, S.-Q., Wang, Y., Mao, M., Liu, Q., et al. (2021) · Cell Research · doi:10.1038/s41422-021-00528-3 · Cited by 170
Scholz, A., Harter, P. N., Cremer, S., Yalcin, B. H., Gurnik, S., Yamaji, M., Di Tacchio, M., Sommer, K., Baumgarten, P., Bähr, O., et al. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201505505 · Cited by 169
MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers
Fultang, L., Panetti, S., Ng, M., Collins, P., Graef, S., Rizkalla, N., Booth, S., Lenton, R., Noyvert, B., Shannon-Lowe, C., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.025 · Cited by 169
Myeloid Cells in Glioblastoma Microenvironment
Leo, A. D., Ugolini, A., & Veglia, F. (2020) · Cells · doi:10.3390/cells10010018 · Cited by 169
Kraus, T. F. J., Globisch, D., Wagner, M., Eigenbrod, S., Widmann, D., Münzel, M., Müller, M., Pfaffeneder, T., Hackner, B., Feiden, W., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27429 · Cited by 168
Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy
Thaci, B., Brown, C. E., Binello, E., Werbaneth, K., Sampath, P., & Sengupta, S. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou045 · Cited by 168
CNS-Native Myeloid Cells Drive Immune Suppression in the Brain Metastatic Niche through Cxcl10
Guldner, I. H., Wang, Q., Yang, L., Golomb, S. M., Zhao, Z., Lopez, J. A., Brunory, A., Howe, E. N., Zhang, Y., Palakurthi, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.064 · Cited by 168
Haverkamp, J. M., Smith, A. M., Weinlich, R., Dillon, C. P., Qualls, J. E., Neale, G., Koss, B., Kim, Y., Bronte, V., Herold, M. J., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.020 · Cited by 167
Convection-enhanced delivery for the treatment of glioblastoma
Vogelbaum, M. A., & Aghi, M. K. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou354 · Cited by 167
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites
Perng, P., & Lim, M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00153 · Cited by 166
Ban, Y., Mai, J., Li, X., Mitchell-Flack, M., Zhang, T., Zhang, L., Chouchane, L., Ferrari, M., Shen, H., & Ma, X. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2913 · Cited by 166
Chen, D., Le, S. B., Hutchinson, T. E., Calinescu, A.-A., Sebastian, M., Jin, D., Liu, T., Ghiaseddin, A. P., Rahman, M., & Tran, D. D. (2022) · Journal of Clinical Investigation · doi:10.1172/jci149258 · Cited by 166
GABA’s Control of Stem and Cancer Cell Proliferation in Adult Neural and Peripheral Niches
Young, S. Z., & Bordey, A. (2009) · Physiology · doi:10.1152/physiol.00002.2009 · Cited by 165
Pathania, R., Ramachandran, S., Mariappan, G., Thakur, P., Shi, H., Choi, J.-H., Manicassamy, S., Kolhe, R., Prasad, P. D., Sharma, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2249 · Cited by 165
Immune Checkpoint in Glioblastoma: Promising and Challenging
Huang, J., Liu, F., Liu, Z., Tang, H., Wu, H., Gong, Q.-N., & Chen, J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00242 · Cited by 165
Babic, I., Anderson, E. S., Tanaka, K., Guo, D., Masui, K., Li, B., Zhu, S., Gu, Y., Villa, G. R., Akhavan, D., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.013 · Cited by 164
Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma
Naghavian, R., Faigle, W., Oldrati, P., Wang, J., Toussaint, N. C., Qiu, Y., Medici, G., Wacker, M., Freudenmann, L. K., Bonté, P.-E., et al. (2023) · Nature · doi:10.1038/s41586-023-06081-w · Cited by 163
Role of galectin 3 binding protein in cancer progression: a potential novel therapeutic target
Capone, E., Iacobelli, S., & Sala, G. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03085-w · Cited by 163
Myeloid-derived suppressor cells inhibit T cell activation through nitrating LCK in mouse cancers
Feng, S., Cheng, X., Zhang, L., Lu, X., Chaudhary, S., Teng, R., Frederickson, C. E., Champion, M. M., Zhao, R., Liang Cheng, C., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1800695115 · Cited by 162
Zhang, P., Miska, J., Lee-Chang, C., Rashidi, A., Panek, W. K., An, S., Zannikou, M., Lopez-Rosas, A., Han, Y., Xiao, T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906346116 · Cited by 162
Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
Aslan, K., Turco, V., Blobner, J., Sonner, J. K., Liuzzi, A. R., Núñez, N. G., De Feo, D., Kickingereder, P., Fischer, M., Green, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14642-0 · Cited by 162
Oncolytic virus therapy in cancer: A current review
Santos Apolonio, J., Lima de Souza Gonçalves, V., Cordeiro Santos, M. L., Silva Luz, M., Silva Souza, J. V., Rocha Pinheiro, S. L., de Souza, W. R., Sande Loureiro, M., & de Melo, F. F. (2021) · World Journal of Virology · doi:10.5501/wjv.v10.i5.229 · Cited by 162
Olfactory sensory experience regulates gliomagenesis via neuronal IGF1
Chen, P., Wang, W., Liu, R., Lyu, J., Zhang, L., Li, B., Qiu, B., Tian, A., Jiang, W., Ying, H., et al. (2022) · Nature · doi:10.1038/s41586-022-04719-9 · Cited by 162
Self-citationSteven, A., & Seliger, B. (2016) · Oncotarget · doi:10.18632/oncotarget.7721 · Cited by 161
Guo, X., Qiu, W., Wang, J., Liu, Q., Qian, M., Wang, S., Zhang, Z., Gao, X., Chen, Z., Guo, Q., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32052 · Cited by 161
Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas
LeFave, C. V., Squatrito, M., Vorlová, S., Rocco, G., Brennan, C., Holland, E. C., Pan, Y., & Cartegni, L. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.259 · Cited by 160
Wang, J., Veirman, K. D., Beule, N. D., Maes, K., Bruyne, E. D., Valckenborgh, E. V., Vanderkerken, K., & Menu, E. (2015) · Oncotarget · doi:10.18632/oncotarget.6083 · Cited by 160
Harris‐Bookman, S., Mathios, D., Martin, A. M., Xia, Y., Kim, E., Xu, H., Belcaid, Z., Polanczyk, M., Barberi, T., Theodros, D., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31661 · Cited by 160
Li, X., Su, X., Liu, R., Pan, Y., Fang, J., Cao, L., Feng, C., Shang, Q., Chen, Y., Shao, C., et al. (2021) · Oncogene · doi:10.1038/s41388-020-01636-x · Cited by 160
Alghamri, M. S., Banerjee, K., Mujeeb, A., Mauser, A., Taher, A. W., Thalla, R., McClellan, B. L., Varela, M. L., Stamatovic, S. M., Martínez-Revollar, G., et al. (2022) · ACS Nano · doi:10.1021/acsnano.1c07492 · Cited by 160
Alban, T. J., Bayik, D., Otvos, B., Rabljenovic, A., Leng, L., Jia-Shiun, L., Roversi, G., Lauko, A., Momin, A. A., Mohammadi, A. M., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01191 · Cited by 159
Kunwar, S. (2003) · Local Therapies for Glioma Present Status and Future Developments · doi:10.1007/978-3-7091-6090-9_16 · Cited by 158
Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients
Wang, Q.-T., Nie, Y., Sun, S.-N., Lin, T., Han, R.-J., Jiang, J., Li, Z., Li, J.-Q., Xiao, Y.-P., Fan, Y.-Y., et al. (2020) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02496-w · Cited by 158
Ugolini, A., Tyurin, V. A., Tyurina, Y. Y., Tcyganov, E. N., Donthireddy, L., Kagan, V. E., Gabrilovich, D. I., & Veglia, F. (2020) · JCI Insight · doi:10.1172/jci.insight.138581 · Cited by 158
Khalsa, J. K., Cheng, N., Keegan, J., Chaudry, A., Driver, J., Bi, W. L., Lederer, J., & Shah, K. (2020) · Nature Communications · doi:10.1038/s41467-020-17704-5 · Cited by 158
Chloride Accumulation Drives Volume Dynamics Underlying Cell Proliferation and Migration
Habela, C. W., Ernest, N. J., Swindall, A. F., & Sontheimer, H. W. (2008) · Journal of Neurophysiology · doi:10.1152/jn.90840.2008 · Cited by 154
Mohme, M., Schliffke, S., Maire, C. L., Rünger, A., Glau, L., Mende, K. C., Matschke, J., Gehbauer, C., Akyüz, N., Zapf, S., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2617 · Cited by 154
Pérez, C., Botta, C., Zabaleta, A., Puig, N., Cedena, M., Goicoechea, I., Alameda, D., José‐Eneriz, E. S., Merino, J., Rodríguez‐Otero, P., et al. (2020) · Blood · doi:10.1182/blood.2019004537 · Cited by 154
Innate immune cells in the tumor microenvironment
Li, M. O., Wolf, N. K., Raulet, D. H., Akkari, L., Pittet, M. J., Rodríguez, P. C., Kaplan, R. N., Munitz, A., Zhang, Z., Cheng, S., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.016 · Cited by 154
Kim, Y., Kim, E. H., Wu, Q., Guryanova, O. A., Hitomi, M., Lathia, J. D., Serwanski, D. R., Sloan, A. E., Weil, R. J., Lee, J., et al. (2012) · Genes & Development · doi:10.1101/gad.193565.112 · Cited by 153
Ni, X., Wu, W.-C., Sun, X., Ma, J.-X., Yü, Z., He, X., Cheng, J., Xu, P., Liu, H., Shang, T., et al. (2022) · Science Advances · doi:10.1126/sciadv.abl5165 · Cited by 153
Polewski, M. D., Reveron‐Thornton, R. F., Cherryholmes, G. A., Marinov, G. K., Cassady, K. M., & Aboody, K. S. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0028 · Cited by 151
Cited by
From Biomarkers to Behavior: Mapping the Neuroimmune Web of Pain, Mood, and Memory
Tanaka, M., & Battaglia, S. (2025) · Biomedicines · doi:10.3390/biomedicines13092226 · Cited by 13
Metadata
- Authors
- Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y.
- Venue
- Journal of Hematology & Oncology
- Published
- 2024-05-08
- Volume
- 17
- Issue
- 1
- Pages
- 31-31
- ISSN
- 1756-8722 (ISSN-L)
- OpenAlex
- W4396735748
- Cited by
- 392
- References
- 784
- FWCI
- 91.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.